hepatitis

Merck has reported interim results from the ongoing C-WORTHy study, a multi-arm Phase II clinical trial assessing the efficacy and safety of an all-oral, once-daily regimen combining MK-5172 and MK-8742 in patients with chronic HCV Genotype 1 infection (GT1).

The randomised, dose-responsive, parallel-group, multiple-site, double-blind C-WORTHy trial is comparing different patient populations exposed to different durations of treatment of MK-5172 (100mg once-daily) in combination with MK-8742 (50mg once-daily) with or without ribavirin (RBV) in subjects with chronic HCV infection.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

MK-5172 is an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, while MK-8742 is an investigational HCV NS5A replication complex inhibitor.

Interim analysis of patients administered MK-5172/MK-8742 with and without RBV for 12 or 18 weeks showed sustained viral response (SVR), 4 to 8 weeks after the completion of therapy.

In HCV GT1 infected, treatment-naïve cirrhotic patients, MK-5172/MK-8742 treated 97% for 12 and 18 weeks, and MK-5172/MK-8742 plus RBV treated 90% and 97% for 12 and 18 weeks respectively.

See Also:

In HCV GT1 infected prior-null responder patients, MK-5172/MK-8742 treated 91% and 97% for 12 and 18 weeks, respectively, while MK-5172/MK-8742 plus RBV treated 94% and 100% for the 12 and 18 weeks respectively.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"These findings provide additional clinical evidence regarding the potential of MK-5172/MK-8742 in treating a broad spectrum of HCV patients."

The company said that in treatment-naïve, non-cirrhotic patients with HCV/HIV co-infection, MK-5172/MK-8742 treated 90% for 12 weeks and MK-5172/MK-8742 plus RBV 97% for 12 weeks.

The Texas Liver Institute vice-president of scientific and research development and University of Texas Health Science Center clinical professor of medicine Eric Lawitz said there is still a need for further options for the most difficult-to-cure patients, including those with cirrhosis and HCV/HIV co-infection.

"These findings provide additional clinical evidence regarding the potential of MK-5172/MK-8742 in treating a broad spectrum of HCV patients," Lawitz said.

The company has enrolled a total of 471 patients with chronic HCV GT1 and HCV RNA levels of =10,000IU/mL in the trial and randomised across 16 arms.

Most common adverse events seen among treatment-naïve patients with cirrhosis and prior-null responder patients with and without cirrhosis were fatigue, headache, and asthenia.

The most common adverse events seen among HIV co-infected patients were headache, asthenia, fatigue, and sleep disorder.

Image: C-WORTHy study is a multi-arm Phase II study. Photo: courtesy of freedigitalphotos.net.